Clinical Trial

A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-04
notable Primary completion pushed: 2025-08 -> 2026-04-01 2026-08-04
minor Completion pushed: 2027-09 -> 2028-02 2026-08-04
Trial Details
NCT Number NCT05737784
Lead Sponsor Praxis Precision Medicines
Conditions SCN2A-DEE, Epilepsy
Enrollment 60 participants
Start Date 2023-04-13
Primary Completion 2026-04-01 (estimated)
Study Completion 2028-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-03